

Date: 17/05/2019

To
Deputy Manager
Dept. of Corporate Services,
BSE Limited
P J Towers, Dalal Street,
Fort, MUMBAI - 400001

Sub: Outcome of Board Meeting held on 17th May, 2019.

Ref: Script Code# 511509

With reference to subject cited above, we would like to inform you that the Directors met today i.e., 17th May, 2019 and transacted following business:


1. Approved Audited Standalone and Consolidated financial results for the quarter and year ended on 31st March, 2019. In compliance with the Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are herewith enclosing Audited Standalone and Consolidated Financial results for the Quarter and Year ended on 31st March, 2019 along with Audit Report issued by the Statutory Auditors of the company. we are herewith enclosing Declaration under Regulation 33(3)(d) of SEBI(Listing Obligation and Disclosure Requirements) Regulation,2015.
2. Accepted resignation of Mr .Ch Varun Kumar, Company Secretary and Compliance Officer (Membership No: 31280 of ICSI) of the Company and he will be relieved from his services from the closing hours of 18th May,2019.
3. Approved Appointment of Mr. Tejomurthula Viswaswara Kaladhar Kuppambhotla (DIN:08450361) as Additional Director and Executive Director of the Company, whose brief profile is enclosed. The company hereby affirms that Mr. Tejomurthula Viswaswara Kaladhar Kuppambhotla, Director being appointed is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority as on date of appointment

The Meeting started at 5.00 PM and ended at 9.10 PM

This is for your record and reference.

Yours truly,

For Vivo Bio Tech Limited


M Kalyan Ram
Whole Time Director
DIN. 02012580

1.Name	Tejomurthula Viswaswara Kaladhar Kuppambhotla
Date of Birth	17 th February,1973
Date of Appointment	17 th May,2019
Qualifications:	M.Com
Expertise in Specific Functional Areas:	20 years of experience in Finance , Accounting, Audit & Taxations Fields across multiple industries. Worked with M/s. Vijaya Diagnostic Centre Pvt Ltd and was in-charge of the Fund Management and Statutory Compliances. Worked with Ratanam Dhaveji & Co, Chartered Accounts in the area of Internal & Statutory Audits.
Directorships held in other public companies (Excluding Foreign companies and Section 8 Companies)	NIL
Memberships/Chairmanships of Committees of other public Companies (Includes Only Audit Committee and Stakeholder's Relationship Committee)	NIL
Number of shares held in the company	NIL
Relationship between directors inter-se	There is no relationship with other directors on the board

Tejomurthula

Date: 17/05/2019

To
Deputy Manager
Dept. of Corporate Services,
BSE Limited
P J Towers, Dalal Street,
Fort, MUMBAI - 400001

Declaration Pursuant to Regulation 33(3)(d) of SEBI(Listing Obligation and Disclosure Requirements) Regulation,2015.

Sub: Declaration for Unmodified opinion


Ref: Script Code# 511509


I, M Kalyan Ram, Whole Time Director of the Company, hereby declare that the Statutory Auditors of the Company M/s. P C N & Associates, Chartered Accountants (Firm Registration No.016016S) have issued unmodified opinion on financial results of the Company for the financial year ended and quarter ended on 31st March,2019.

The Declaration is issued in compliance with Reg.33 (3)(d) SEBI (Listing Obligation and Disclosure Requirements) Regulation,2015 as amended vide Circular No. CIR/CFD/CMD/56/2016 dated 27th May, 2016.

For Vivo Bio Tech Limited

M Kalyan Ram
Whole Time Director
DIN: 02012580

Statement of Consolidated Audited Financial Results for the Quarter and Year ended on 31st March,2019						Rs in Lakhs	
S.No.	PARTICULARS	QUARTER ENDED			Year Ended		
		31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018	
		Audited	Unaudited	Audited	Audited	Audited	
I	Revenue from operations	1,376.50	1,442.10	1,232.96	5,583.35	4,700.12	
II	Other income		-	0.61	1.21	13.35	
III	Total Income	1,376.50	1,442.10	1,233.57	5,584.56	4,713.47	
IV	Expenses						
	a) Increase/(decrease) in stock in trade and WIP	79.31	88.41	90.37	(65.01)	(302.77)	
	b) Consumption of Raw materials	-	-	-	-	-	
	c) Purchase of traded goods	218.33	187.74	326.03	1,240.92	1,259.60	
	d) Employees Cost	300.61	231.15	173.45	957.80	758.52	
	e) Depreciation and amortisation	126.44	134.56	92.02	505.77	463.94	
	f) Finance Cost	63.52	65.32	61.84	264.09	236.75	
	g)Administrative Expenditure	524.30	611.32	377.44	2,119.96	1,896.81	
	Total	1,312.51	1,318.50	1,121.15	5,023.54	4,312.85	
IX	Profit before tax and Exceptional Items	64.00	123.60	112.43	561.02	400.61	
	Exceptional items	378.36	-	-	378.36	-	
X	Profit before tax	(314.36)	123.60	112.43	182.65	400.61	
VI	Tax Expense						
	a. Current Tax	(80.60)	41.48	55.50	37.60	110.42	
	b. Deffered tax	63.93	(44.14)	(22.98)	(79.93)	(21.94)	
VII	Profit (Loss) for the period (XI + XIV)	(297.70)	126.26	79.91	224.98	312.13	
VIII	Other Comprehensive Income(Net of Tax)		-	0.28		1.13	
IX	Total Comprehensive Income(XV+XVI)	(297.70)	126.26	80.19	224.98	313.26	
X	Paid Up Share Capital (Face value of Rs.10/-)	1,235.05	995.05	985.05	1,235.05	985.05	
XI	Earnings per equity share:						
	1)Basic	(2.41)	1.27	0.82	1.82	3.18	
	2)Diluted	(2.33)	0.99	0.82	1.76	2.36	
Place: Hyderabad				For Vivo Bio Tech Limited			
Dated:17/05/2019				 M.KALYAN RAM WHOLE TIME DIRECTOR DIN:02012580			

Consolidated Statement of Assets and Liabilities		In Lakhs	
S.No	Particulars	As AT 31/03/2019 Audited	As AT 31/03/2018 Audited
A	ASSETS		
1	Non-Current Assets		
	a)Fixed Assets		
	Property, Plant and Equipment	2,480.42	2,131.06
	Capital Work-In-Progress	6.60	394.43
	Intangible Assets	520.81	635.06
	Financial A ssets		
	Other non-current assets	11.38	3.91
	Total Non-Current Assets	3,019.21	3,164.45
2	Current Assets		
	a) Inventories	823.63	758.62
	Financial Assets		
	b) Trade Receivables	841.00	1,177.65
	c)Cash and cash equivalents	56.27	415.10
	d) short term loans and advances	712.47	381.34
	Other current assets	54.93	53.86
	Total Current Assets	2,488.29	2,786.57
	TOTAL ASSETS	5,507.51	5,951.02
B	EQUITY AND LIABILITIES		
1	Equity		
	a) Equity Share Capital	1,235.05	985.05
	b) other Equity		
	i) Reserves and Surplus	1,462.20	735.71
	Money Received Against Share Warrants	30.00	210.00
	Total Equity	2,727.25	1,930.76
	Liabilities		
2	Non Current liabilities		
	Financial Liabilities		
	Borrowings	890.46	1,390.33
	Deferred Tax Liabilities(Net)	(23.69)	56.24
	Long term provisions	35.86	30.58
	Total Non Current Liabilities	902.63	1,477.16
3	Current Liabilities		
	Financial Liabilities		
	Borrowings	1,277.23	1,121.41
	Trade Payable	386.77	798.00
	Provisions	110.38	276.88
	Other current Liabilities	103.25	346.81
	Toatal Current Liabilities	1,877.63	2,543.10
	Total Liabilities	5,507.51	5,951.02
Place: Hyderabad		For Vivo Bio Tech Limited	
Dated:17/05/2019		 M.KALYAN RAM WHOLE TIME DIRECTOR DIN:02012580	



P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

Auditor's Report on Quarterly Financial Results and Year to Date Financial Results of VIVO BIO TECH LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

**To Board of Directors of
Vivo Bio Tech Limited**

1. We have audited the accompanying Statement of Consolidated Financial Results of M/s **VIVO BIO TECH LIMITED** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred as "the Group") for the year ended 31st March, 2019 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016("the circular"). This Statement, which is the responsibility of the Holdings Company's management, has been prepared on the basis of the related consolidated financial statements which is in accordance with the Accounting Standards, prescribed under Section 133 of the Companies Act, 2013, as applicable, and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.

2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Holding Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Holding Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

3. We did not audit the financial statements of all the 3 subsidiaries whose financial statements/consolidated financial statements reflect total assets before elimination of Rs. 24,54,786/- as at 31.03.2019 and the total revenue of Rs. Nil for the year then ended which are considered in preparation of the Statement. These interim financial statements and other financial information have been audited by other auditors whose reports have been furnished to us, and our opinion on the quarterly financial results and the year to date results, to the extent they have been derived from such interim financial statements is based solely on the report of such other auditors.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

4. In our opinion and to the best of our information and according to the explanations given to us, these quarterly consolidated financial results as well as the consolidated year to date financial results :


(i) Include the quarterly and year to date financial results of the following entities:


- (a) VIOBIO LABS PRIVATE LIMITED
- (b) VIVO BIO DISCOVERY SERVICES PRIVATE LIMITED
- (c) SURLOGIC LIFE CONSULTANCY PRIVATE LIMITED

(ii) is prepared in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 ; and

(iii) gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and other financial information of the Company for the year ended 31st March 2019.

For P C N & Associates .,
Chartered Accountants
Firm's RegnNo.016016S


Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad
Date: 17th May 2019

Notes

1. The Company has adopted IND AS with effect from 01st April, 2017 with comparatives being restated. Accordingly impact of the of transition has been provided in the previous year's quarterly and year ended results
2. The Financial results and other financial information for the quarter and year ended on 31st March,2019 has been complied by the management as per Ind As, after exercising necessary due diligence to ensure that financial results provide true and fair view of the results in accordance with Ind As. This information has not been subject to any limited review or audit.
3. The above financial results are recommended by the Audit Committee were considered and approved by the board of directors at their meeting held on 17th May, 2019.
4. The Consolidated Results include results of all subsidiaries.

Additional information on Standalone Financial results is as follows:

Rs in Lakhs

Particulars	Quarter Ended			Year Ended	
	31/03/2019	31/12/2018	31/03/2018	31/03/2019	31/03/2018
	Audited	Un-Audited	Audited	Audited	Audited
Income from operations	1,376.50	1,442.10	1,232.96	5,583.35	4,700.12
Profit before tax	(314.36)	123.60	112.60	182.66	400.78
Total Comprehensive Income(PAT)	(297.70)	126.26	80.36	224.99	313.43

5. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
6. An Extract of the detailed format of audited Consolidated Financial results filed with stock exchange will under Regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 will be published in Newspaper.


7. The figures for the current quarter are the balancing figures between the audited figures in respect of full financial year and the published year to date figures up to the third quarter of the respective financial years.
8. The above financial results are available on the stock exchange website www.bseindia.com and company's website www.vivobio.com.
9. Previous year's/period's figures are rearranged/ regrouped wherever necessary.


Date: 17th May, 2019
Place: Hyderabad

For Vivo Bio Tech Limited



M Kalyan Ram
Whole Time Director
DIN: 02012580

Statement of Standalone Audited Financial Results for the Quarter and Year ended on 31st March,2019						Rs in Lakhs	
S.No.	PARTICULARS	QUARTER ENDED			Year Ended		
		31.03.2019	31.12.2018	31.03.2018	31.03.2019	31.03.2018	
		Audited	Unaudited	Audited	Audited	Audited	
I	Revenue from operations	1,376.50	1,442.10	1,232.96	5,583.35	4,700.12	
II	Other income		-	0.61	1.21	13.35	
III	Total Income	1,376.50	1,442.10	1,233.57	5,584.56	4,713.47	
IV	Expenses						
	a) Increase/(decrease) in stock in trade and WIP	79.31	88.41	90.37	(65.01)	(302.77)	
	b) Consumption of Raw materials	-	-	-	-	-	
	c) Purchase of traded goods	218.33	187.74	326.03	1,240.92	1,259.60	
	d) Employees Cost	300.61	231.15	173.45	957.80	758.52	
	e) Depreciation and amortisation	126.44	134.56	92.02	505.77	463.94	
	f) Finance Cost	63.52	65.32	61.84	264.09	236.75	
	g)Administrative Expenditure	524.30	611.32	377.27	2,119.96	1,896.64	
	Total	1,312.51	1,318.50	1,120.98	5,023.54	4,312.68	
IX	Profit before tax and Exceptional Items	64.00	123.60	112.60	561.02	400.78	
	Exceptional items	378.36	-	-	378.36	-	
X	Profit before tax	(314.36)	123.60	112.60	182.66	400.78	
XI	Tax Expense						
	a. Current Tax	(80.60)	41.48	55.50	37.60	110.42	
	b. Deffered tax	63.93	(44.14)	(22.98)	(79.93)	(21.94)	
XII	Profit (Loss) for the period (XI- XII)	(297.70)	126.26	80.08	224.99	312.30	
XIII	Other Comprehensive Income(Net of Tax)	-	-	0.28	-	1.13	
	Total Comprehensive Income(XV+XVI)	(297.70)	126.26	80.36	224.99	313.43	
	Paid Up Share Capital (Face value of Rs.10/-)	1,235.05	995.05	985.05	1,235.05	985.05	
XIV	Earnings per equity share:						
	1)Basic	(2.41)	1.27	0.81	1.82	3.17	
	2)Diluted	(2.33)	0.99	0.82	1.76	2.36	
Place: Hyderabad				For Vivo Bio Tech Limited			
Dated:17/05/2019				 M.KALYAN RAM WHOLE TIME DIRECTOR DIN:02012580			

Standalone Statement of Assets and Liabilities		In Lakhs	
Particulars		As AT 31/03/2019 Audited	As AT 31/03/2018 Audited
A	ASSETS		
1	Non-Current Assets		
	a) Fixed Assets		
	Property, Plant and Equipment	2,461.01	2,111.65
	Capital Work-In-Progress	6.60	394.43
	Intangible Assets	520.81	635.06
	Financial Assets		
	Non-Current Investments	3.00	3.00
	Other non-current assets	9.74	3.91
	Total Non-Current Assets	3,001.17	3,148.05
2	Current Assets		
	a) Inventories	823.63	758.62
	Financial Assets		
	b) Trade Receivables	841.00	1,177.65
	c) Cash and cash equivalents	52.76	414.52
	d) short term loans and advances	734.25	400.13
	Other current assets	54.93	53.86
	Total Current Assets	2,506.57	2,804.77
	TOTAL ASSETS	5,507.74	5,952.82
B	EQUITY AND LIABILITIES		
1	Equity		
	a) Equity Share Capital	1,235.05	985.05
	b) other Equity		
	i) Reserves and Surplus	1,463.19	738.20
	Money Received Against Share Warrants	30.00	210.00
	Total Equity	2,728.24	1,933.25
2	Liabilities		
	Non Current liabilities		
	Financial Liabilities		
	Borrowings	889.94	1,389.81
	Defered Tax Liabilities(Net)	(23.69)	56.24
	Long term provisions	35.86	30.58
	Total Non Current Liabilities	902.11	1,476.64
3	Current Liabilities		
	Financial Liabilities		
	Borrowings	1,277.23	1,121.41
	Trade Payable	386.77	798.00
	Provisions	103.25	346.81
	Other current Liabilities	110.15	276.70
	Toatal Current Liabilities	1,877.40	2,542.93
	Total Liabilities	5,507.74	5,952.82
Place: Hyderabad		For Vivo Bio Tech Limited	
Dated:17/05/2019		 M.KALYAN RAM WHOLE TIME DIRECTOR DIN:02012580	




P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

Auditor's Report on Quarterly Financial Results and Year to Date Financial Results of VIVO BIO TECH LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

To Board of Directors of
Vivo Bio Tech Limited

1. We have audited the quarterly financial results of **Vivo Bio Tech Limited** for the quarter ended March 31, 2019 and to the year to date financial results for the year ended March 31, 2019, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016('the circular'), except for the disclosures regarding Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The quarterly financial results are the derived figures between the audited figures in respect of the year ended March 31, 2019 and the published year-to-date figures up to December 31, 2018, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The financial results for the quarter ended March 31, 2019 have been prepared on the basis of the financial results for the nine-month period ended December 31, 2018, the audited annual financial statements as at and for the year ended March 31, 2019, and the relevant requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these Financial results based on our review of the financial results for the nine-month period ended December 31, 2018 which was prepared in accordance with applicable Ind AS and other recognised accounting policies laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the act, read with rule 7 of the companies(Accounts) Rules 2014 and other accounting principles generally accepted in India; our audit of the annual financial statements as at and for the year ended March 31, 2019; and the relevant requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.
2. These financial results have been prepared on the basis of Ind AS financial statements and reviewed quarterly financial results up to the end of the third quarter, which are the responsibility of Companies Management. Our responsibility is to express an opinion on these financial results based on our Audit of such annual Ind AS Financial statements, which has been prepared in accordance with the recognised and measurements principles laid down in Indian Accounting Standards, prescribed under section 133 of the Companies Act, 2013 and the relevant requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended.





P C N & ASSOCIATES
CHARTERED ACCOUNTANTS
Plot No. 12, "N Heights"
Ground Floor, Software Layout Unit
Cyberabad, Hyderabad - 500 081.

Tel. : (91-40) 2311 9499
E-mail : pcnassociates@yahoo.com

3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.


An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI(Listing Obligations and Disclosures Requirements) Regulations, 2015 , as amended in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2019 as well as the year to date results for the period from April 1, 2018 to March 31, 2019.

For P C N & Associates .,
Chartered Accountants
(Firm's Regn No.016016S)


Chandra Babu M
Partner
M.No. 227849



Place: Hyderabad
Date: 17th May 2019